标题
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
作者
关键词
-
出版物
Nature Reviews Neurology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-09-21
DOI
10.1038/s41582-021-00545-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease
- (2021) Reisa Sperling et al. JAMA Neurology
- Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
- (2021) Kevin D. Rynearson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of neurodegeneration — Insights from familial Alzheimer’s disease
- (2020) Lucía Chávez-Gutiérrez et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- The substrate repertoire of γ-secretase/presenilin
- (2020) Gökhan Güner et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
- (2020) Alette M. Wessels et al. Alzheimers & Dementia
- An optimized quantitative proteomics method establishes the cell type‐resolved mouse brain secretome
- (2020) Johanna Tüshaus et al. EMBO JOURNAL
- Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
- (2020) Joseph W. Lewcock et al. NEURON
- The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloid‐negative APOE4 homozygotes
- (2020) Eric M. Reiman et al. Alzheimers & Dementia
- The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2
- (2020) Marie‐Laure Rouzade‐Dominguez et al. Alzheimers & Dementia
- The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2
- (2020) Pierre N. Tariot et al. Alzheimers & Dementia
- Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out
- (2020) Ana Graf et al. Alzheimers & Dementia
- BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
- (2020) Cyrille Sur et al. BRAIN
- Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life
- (2020) Ruth E. Uhlmann et al. NATURE NEUROSCIENCE
- New Evolutions in the BACE1 Inhibitor Field from 2014 to 2018
- (2019) Chien-Chi Hsiao et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
- (2019) Francesco Panza et al. Nature Reviews Neurology
- A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment
- (2019) Brati Das et al. CNS DRUGS
- Lowering of Amyloid-Beta by β-Secretase Inhibitors — Some Informative Failures
- (2019) David S. Knopman NEW ENGLAND JOURNAL OF MEDICINE
- Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
- (2019) David Henley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
- (2019) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
- (2019) Michael F. Egan et al. Alzheimers Research & Therapy
- Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
- (2019) Alette M. Wessels et al. JAMA Neurology
- BACE1 partial deletion induces synaptic plasticity deficit in adult mice
- (2019) Sylvia Lombardo et al. Scientific Reports
- Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale
- (2018) Michael Navitsky et al. Alzheimers & Dementia
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6
- (2018) Kaichuan Zhu et al. BIOLOGICAL PSYCHIATRY
- Proteolytic ectodomain shedding of membrane proteins in mammals—hardware, concepts, and recent developments
- (2018) Stefan F Lichtenthaler et al. EMBO JOURNAL
- BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions
- (2018) Xiangyou Hu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
- (2018) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision pharmacology for Alzheimer’s disease
- (2018) Harald Hampel et al. PHARMACOLOGICAL RESEARCH
- Controlling of glutamate release by neuregulin3 via inhibiting the assembly of the SNARE complex
- (2018) Ya-Nan Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuregulin 3 promotes excitatory synapse formation on hippocampal interneurons
- (2018) Thomas Müller et al. EMBO JOURNAL
- The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
- (2018) Ulf Neumann et al. EMBO Molecular Medicine
- Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
- (2018) Eric M. Reiman et al. JOURNAL OF ALZHEIMERS DISEASE
- Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice
- (2018) Ming-Hsuan Ou-Yang et al. Science Translational Medicine
- Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
- (2018) Maarten Timmers et al. Alzheimers Research & Therapy
- Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers
- (2018) Andrea Vergallo et al. Alzheimers & Dementia
- Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
- (2017) Konstantinos C Koskinas et al. EUROPEAN HEART JOURNAL
- NONCLINICAL PHARMACOLOGICAL CHARACTERIZATION OF THE BACE1 INHIBITOR LY3202626
- (2016) David L. McKinzie et al. Alzheimers & Dementia
- The Cellular Phase of Alzheimer’s Disease
- (2016) Bart De Strooper et al. CELL
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
- (2016) Susanna Eketjäll et al. JOURNAL OF ALZHEIMERS DISEASE
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons
- (2016) Martina Pigoni et al. Molecular Neurodegeneration
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- The BACE1 inhibitor verubecestat (MK-8931) reduces CNS -amyloid in animal models and in Alzheimers disease patients
- (2016) M. E. Kennedy et al. Science Translational Medicine
- Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors
- (2016) Andrea M. Zuhl et al. Nature Communications
- Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice
- (2016) Derya R. Shimshek et al. Scientific Reports
- η-Secretase processing of APP inhibits neuronal activity in the hippocampus
- (2015) Michael Willem et al. NATURE
- The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain
- (2015) Paul Saftig et al. PROGRESS IN NEUROBIOLOGY
- Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease
- (2015) Zhentao Zhang et al. Nature Communications
- Antagonistic Effects of BACE1 and APH1B-γ-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse
- (2015) Soraia Barão et al. Cell Reports
- Lessons from a Failed γ-Secretase Alzheimer Trial
- (2014) Bart De Strooper CELL
- Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein
- (2014) Janice A. Maloney et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The A4 Study: Stopping AD Before Symptoms Begin?
- (2014) R. A. Sperling et al. Science Translational Medicine
- The Preclinical Alzheimer Cognitive Composite
- (2014) Michael C. Donohue et al. JAMA Neurology
- Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles
- (2013) Cyril Cheret et al. EMBO JOURNAL
- Systematic Proteomic Analysis Identifies β-Site Amyloid Precursor Protein Cleaving Enzyme 2 and 1 (BACE2 and BACE1) Substrates in Pancreatic β-Cells
- (2013) Ina Stützer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dual Cleavage of Neuregulin 1 Type III by BACE1 and ADAM17 Liberates Its EGF-Like Domain and Allows Paracrine Signaling
- (2013) D. Fleck et al. JOURNAL OF NEUROSCIENCE
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells
- (2013) L. Rochin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
- (2013) S.M. Mills et al. REVUE NEUROLOGIQUE
- BACE1 Regulates Hippocampal Astrogenesis via the Jagged1-Notch Pathway
- (2013) Xiangyou Hu et al. Cell Reports
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons
- (2012) Peer-Hendrik Kuhn et al. EMBO JOURNAL
- β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment
- (2012) Jun Cai et al. EMBO Molecular Medicine
- β-Site Amyloid Precursor Protein (APP)-cleaving Enzyme 1 (BACE1)-deficient Mice Exhibit a Close Homolog of L1 (CHL1) Loss-of-function Phenotype Involving Axon Guidance Defects
- (2012) Brian Hitt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Proteasein Vivo
- (2012) Lujia Zhou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology
- (2012) Pritam Das et al. Molecular Neurodegeneration
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease
- (2012) Luxiang Cao et al. Scientific Reports
- Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass
- (2011) Daria Esterházy et al. Cell Metabolism
- Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
- (2011) Todd E. Golde et al. NEURON
- ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons
- (2010) Peer-Hendrik Kuhn et al. EMBO JOURNAL
- The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex
- (2010) E. Jorissen et al. JOURNAL OF NEUROSCIENCE
- Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice
- (2009) R. A. Karlnoski et al. JOURNAL OF NEUROSCIENCE
- Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
- (2009) Matthew L. Hemming et al. PLoS One
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started